0.00Open0.00Pre Close0 Volume0 Open Interest0.50Strike Price0.00Turnover0.00%IV-95.46%PremiumJul 19, 2024Expiry Date10.51Intrinsic Value100Multiplier-1DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma--Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Atara Biotherapeutics Stock Discussion
Atara Biotherapeutics- Bla Acceptance Triggers $20 Mln Milestone Payment With Additional $60 Mln Milestone if Approved by FDA
Atara Biotherapeutics - Preclinical Results Support Advancing ATA3219 Towards Clinical Evaluation in Patients With B-Cell Driven Autoimmune Diseases
Atara Biotherapeutics Presents Preclinical Data on ATA3219, an Allogeneic CD19-Targeted CAR T Therapy for the Treatment of B-Cell Driven Autoimmune Diseases, at the ISCT 2024 Annual Meeting
Atara Biotherapeutics has announced promising preclinical data for ATA3219, an allogeneic CD19-targeted CAR T therapy aimed at treating B-cell driven autoimmune diseases such as systemic lupus erythematosus (SLE) and multiple sclerosis (MS). The data, to be presented at th...
NEWS
Atara Biotherapeutics Submits Tabelecleucel (Tab-cel®) Biologics License Application for Treatment of Epstein-Barr Virus Positive Post-Transplant Lymphoproliferative Disease with U.S. FDA
05/20/2024 - 06:25 AM First Allogeneic T-Cell Therapy BLA Submission to U.S. Food and Drug Administration If Approved, Tab-cel Would be First Approved Therapy in U.S. for EBV+ PTLD Acceptance of BLA Will Trigger $20 Million Milestone Payment from Pierre Fabre Laboratories, ...
Allogeneic CAR T Pipeline Expands Into Autoimmune Disease With Plans To Initiate a ATA3219 Lupus Nephritis Study in H2 2024, and Initial Clinical Data Expected H1 2025
ATA3219 NHL Study Enrolling With Initial Clinical Data Expected in Q4 2024
Cash Runway Into 2027 Enables Key Pipeline Readouts
SEC announcement· 4 mins ago
No comment yet